Literature DB >> 32502448

Top ten research priorities for pancreatic cancer therapy.

Rosa Klotz1, Colette Doerr-Harim2, Azaz Ahmed3, Christine Tjaden4, Maryrose Tarpey5, Markus K Diener1, Thilo Hackert4, André L Mihaljevic6.   

Abstract

Entities:  

Year:  2020        PMID： 32502448     DOI： 10.1016/S1470-2045(20)30179-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  6 in total

1.  Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership.

Authors:  Rosa Klotz; Magdalena Holze; Colette Dörr-Harim; Erich Grohmann; Barbara Nied; Burkhard Lebert; Susanne Weg-Remers; Claudia Lutz; Karin Meißler; Patrick Schloss; Charlotte Ullrich; Susanne Frankenhauser; Heidi Lutter; Diedrich Bühler; Azaz Ahmed; Toto Gronlund; André L Mihaljevic
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-17       Impact factor: 4.553

2.  Alizarin, a nature compound, inhibits the growth of pancreatic cancer cells by abrogating NF-κB activation.

Authors:  Zihang Xu; Yifei Hou; Chunpu Zou; Haibin Liang; Jiasheng Mu; Xiaoning Jiao; Yangzhuangzhuang Zhu; Lin Su; Mingxi Liu; Xiao Chen; Chunmei Qian; Xiandan Zhu; Wei Gong; Qian Dong; Fei Zhang
Journal:  Int J Biol Sci       Date:  2022-03-28       Impact factor: 10.750

3.  James Lind Alliance Priority Setting Partnership for Degenerative Cervical Myelopathy [AO Spine RECODE-DCM]: An Overview of the Methodology Used to Process and Short-List Research Uncertainties.

Authors:  Lindsay Tetreault; Oliver Mowforth; Danyal Z Khan; Toto Gronlund; Philip Garwood; Olesja Hazenbiller; James S Harrop; Bizhan Aarabi; Vafa Rahimi-Movaghar; Shekar N Kurpad; James D Guest; Jefferson R Wilson; Brian K Kwon; Michael G Fehlings; Benjamin M Davies; Mark R N Kotter
Journal:  Global Spine J       Date:  2022-02

4.  Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis.

Authors:  Zhu Zeng; Yong Zhao; QingYong Chen; Shuai Zhu; Yi Niu; Zeng Ye; Ping Hu; Ding Chen; Peng Xu; Jinghuang Chen; Chaojie Hu; Yuhang Hu; Fengyu Xu; Jiang Tang; Fan Wang; Shengbo Han; Mengqi Huang; Chunyou Wang; Gang Zhao
Journal:  Oncogene       Date:  2021-07-22       Impact factor: 9.867

5.  Protocol for a randomised controlled trial to compare postoperative complications between minimally invasive and open DIStal PAnCreaTectomy (DISPACT-2 trial).

Authors:  Pascal Probst; Fabian Schuh; Colette Dörr-Harim; Anja Sander; Thomas Bruckner; Christina Klose; Inga Rossion; Felix Nickel; Beat Peter Müller-Stich; Arianeb Mehrabi; Thilo Hackert; Markus W Büchler; Markus K Diener
Journal:  BMJ Open       Date:  2021-02-22       Impact factor: 2.692

6.  Pancreatic resection with perioperative drug repurposing of propranolol and etodolac: trial protocol of the phase-II randomised placebo controlled PROSPER trial.

Authors:  Felix J Hüttner; Ilse Rooman; Gauthier Bouche; Phillip Knebel; Johannes Hüsing; André L Mihaljevic; Thilo Hackert; Oliver Strobel; Markus W Büchler; Markus K Diener
Journal:  BMJ Open       Date:  2020-09-30       Impact factor: 2.692
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.